TET protein inhibitors: Potential and limitations

ENPřihlásit se Přihlásit se (EduID)

Přehled o publikaci

J 2023

TET protein inhibitors: Potential and limitations

KAPLÁNEK, Robert; Zdeněk KEJÍK; Jan HAJDUCH; Kateřina VESELÁ; Kateřina KUČNIROVÁ et. al.

Základní údaje

Originální název

TET protein inhibitors: Potential and limitations

Autoři

Vydání

PHARMACOTHERAPY, Paris, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, 0753-3322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Lékařská fakulta – Masarykova univerzita – Repozitář

DOI

http://dx.doi.org/10.1016/j.biopha.2023.115324

UT WoS

001060916100001

EID Scopus

2-s2.0-85168132692

Klíčová slova anglicky

TET protein; Inhibitor; Cancer; Therapy; Mitochondria

Návaznosti

LM2023053, projekt VaV. LX22NPO5102, projekt VaV. LX22NPO5107, projekt VaV. NU21-09-00541, projekt VaV. TN01000013, projekt VaV. TN02000109, projekt VaV. EATRIS-CZ IV, velká výzkumná infrastruktura.

Změněno: 25. 11. 2023 03:21, RNDr. Daniel Jakubík

Anotace

V originále

TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.

Přiložené soubory

https://is.muni.cz/publication/2305123/TET_protein_inhibitors_Potential_and_limitations.pdf

Citovat

KAPLÁNEK, Robert; Zdeněk KEJÍK; Jan HAJDUCH; Kateřina VESELÁ; Kateřina KUČNIROVÁ; Markéta SKALIČKOVÁ; Anna VENHAUEROVÁ; Božena HOSNEDLOVÁ; Róbert HROMÁDKA; Petr DYTRYCH; Petr NOVOTNÝ; Nikita ABRAMENKO; Veronika ANTONYOVÁ; David HOSKOVEC; Petr BABULA; Michal MASAŘÍK; Pavel MARTÁSEK a Milan JAKUBEK. TET protein inhibitors: Potential and limitations. PHARMACOTHERAPY. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, roč. 166, October 2023, s. 1-15. ISSN 0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2023.115324.

@article{57266,
   author = {Kaplánek, Robert and Kejík, Zdeněk and Hajduch, Jan and Veselá, Kateřina and Kučnirová, Kateřina and Skaličková, Markéta and Venhauerová, Anna and Hosnedlová, Božena and Hromádka, Róbert and Dytrych, Petr and Novotný, Petr and Abramenko, Nikita and Antonyová, Veronika and Hoskovec, David and Babula, Petr and Masařík, Michal and Martásek, Pavel and Jakubek, Milan},
   article_location = {Paris},
   article_number = {October 2023},
   doi = {http://dx.doi.org/10.1016/j.biopha.2023.115324},
   keywords = {TET protein; Inhibitor; Cancer; Therapy; Mitochondria},
   language = {eng},
   issn = {0753-3322},
   journal = {PHARMACOTHERAPY},
   title = {TET protein inhibitors: Potential and limitations},
   url = {https://www.sciencedirect.com/science/article/pii/S0753332223011150?via%3Dihub},
   volume = {166},
   year = {2023}
}

TY  - JOUR
ID  - 57266
AU  - Kaplánek, Robert - Kejík, Zdeněk - Hajduch, Jan - Veselá, Kateřina - Kučnirová, Kateřina - Skaličková, Markéta - Venhauerová, Anna - Hosnedlová, Božena - Hromádka, Róbert - Dytrych, Petr - Novotný, Petr - Abramenko, Nikita - Antonyová, Veronika - Hoskovec, David - Babula, Petr - Masařík, Michal - Martásek, Pavel - Jakubek, Milan
PY  - 2023
TI  - TET protein inhibitors: Potential and limitations
JF  - PHARMACOTHERAPY
VL  - 166
IS  - October 2023
SP  - 1-15
EP  - 1-15
PB  - ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
SN  - 0753-3322
KW  - TET protein
KW  - Inhibitor
KW  - Cancer
KW  - Therapy
KW  - Mitochondria
UR  - https://www.sciencedirect.com/science/article/pii/S0753332223011150?via%3Dihub
N2  - TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.
ER  -

KAPLÁNEK, Robert; Zdeněk KEJÍK; Jan HAJDUCH; Kateřina VESELÁ; Kateřina KUČNIROVÁ; Markéta SKALIČKOVÁ; Anna VENHAUEROVÁ; Božena HOSNEDLOVÁ; Róbert HROMÁDKA; Petr DYTRYCH; Petr NOVOTNÝ; Nikita ABRAMENKO; Veronika ANTONYOVÁ; David HOSKOVEC; Petr BABULA; Michal MASAŘÍK; Pavel MARTÁSEK a Milan JAKUBEK. TET protein inhibitors: Potential and limitations. \textit{PHARMACOTHERAPY}. Paris: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023, roč.~166, October 2023, s.~1-15. ISSN~0753-3322. Dostupné z: https://dx.doi.org/10.1016/j.biopha.2023.115324.